DexCom, Inc.: peers
DexCom, Inc. beside the 7 companies most like it by industry, size and country: every figure with its date and source, its rank in the group and its percentile in its sector and country.
Side by side#
Every figure with its fiscal year or date and its source. Switch to each company's rank in the group, or its percentile in its sector or country. How ranks are worked out.
| Measure | DexCom, Inc.base DXCM · 🇺🇸 US Percentile in Healthcare Percentile in USA | Mettler-Toledo International Inc. MTD · 🇺🇸 US Percentile in Healthcare Percentile in USA | Quest Diagnostics Incorporated DGX · 🇺🇸 US Percentile in Healthcare Percentile in USA | Labcorp Holdings Inc. LH · 🇺🇸 US Percentile in Healthcare Percentile in USA | Guardant Health, Inc. GH · 🇺🇸 US Percentile in Healthcare Percentile in USA | Illumina, Inc. ILMN · 🇺🇸 US Percentile in Healthcare Percentile in USA | IDEXX Laboratories, Inc. IDXX · 🇺🇸 US Percentile in Healthcare Percentile in USA | Waters Corporation WAT · 🇺🇸 US Percentile in Healthcare Percentile in USA | Group median |
|---|---|---|---|---|---|---|---|---|---|
| Size | |||||||||
| Market cap (Better neither way: ranked highest first) | $29.9 BOct 22, 2026 · Market data5th of 8 | $32.5 BOct 21, 2026 · Market data4th of 8 | $27.8 BOct 30, 2026 · Market data6th of 8 | $26.3 BOct 22, 2026 · Market data7th of 8 | $24.1 BOct 28, 2026 · Market data8th of 8 | $40.7 BOct 26, 2026 · Market data3rd of 8 | $41.5 BOct 6, 2026 · Market data2nd of 8 | $44.8 BOct 27, 2026 · Market data1st of 8 | $31.2 B8 ranked |
| Revenue (Better neither way: ranked highest first) | $4.7 BFY2025 · SEC3rd of 8 | $4.0 BFY2025 · SEC6th of 8 | $11.0 BFY2025 · SEC2nd of 8 | $14.0 BFY2025 · SEC1st of 8 | $982 MFY2025 · SEC8th of 8 | $4.3 BFY2025 · SEC4th of 8 | $4.3 BFY2025 · SEC5th of 8 | $3.2 BFY2025 · SEC7th of 8 | $4.3 B8 ranked |
| Net income (Higher is better) | $836 MFY2025 · SEC6th of 8 | $869 MFY2025 · SEC4th of 8 | $992 MFY2025 · SEC2nd of 8 | $877 MFY2025 · SEC3rd of 8 | $-416 MFY2025 · SEC8th of 8 | $850 MFY2025 · SEC5th of 8 | $1.1 BFY2025 · SEC1st of 8 | $643 MFY2025 · SEC7th of 8 | $860 M8 ranked |
| Employees (Better neither way: ranked highest first) | 11,100December 31, 2025 · Profile3rd of 8 | 1,600December 31, 2025 · Profile8th of 8 | 57,000December 31, 2025 · Profile2nd of 8 | 80,000As on 2022 · Profile1st of 8 | 2,506December 31, 2025 · Profile7th of 8 | 10,200As on Jan-2023 · Profile5th of 8 | 10,780As on 2022 · Profile4th of 8 | 8,200As on 2022 · Profile6th of 8 | 10,4908 ranked |
| Growth | |||||||||
| Market cap change, 30 days (Higher is better) | —— | —— | +8.9%30 days to Oct 30, 2026 · Market dataonly one with it | —— | —— | —— | —— | —— | +8.9%— |
| Revenue growth (Higher is better) | +15.6%FY2025 · SEC2nd of 860th72nd | +4.0%FY2025 · SEC7th of 834th42nd | +11.8%FY2025 · SEC3rd of 854th65th | +7.3%FY2025 · SEC5th of 843rd53rd | +32.9%FY2025 · SEC1st of 879th87th | -0.7%FY2025 · SEC8th of 824th27th | +10.4%FY2025 · SEC4th of 851st63rd | +7.0%FY2025 · SEC6th of 842nd52nd | +8.8%8 ranked |
| Revenue growth, 3 years a year (Higher is better) | +17.0%FY2025 · SEC2nd of 868th82nd | +0.9%FY2025 · SEC7th of 829th36th | +3.7%FY2025 · SEC5th of 838th48th | +5.5%FY2025 · SEC4th of 843rd55th | +29.8%FY2025 · SEC1st of 881st92nd | -1.8%FY2025 · SEC8th of 822nd26th | +8.5%FY2025 · SEC3rd of 850th65th | +2.1%FY2025 · SEC6th of 833rd41st | +4.6%8 ranked |
| Earnings per share growth (Higher is better) | +47.2%FY2025 · SEC1st of 675th80th | +3.9%FY2025 · SEC5th of 642nd43rd | +13.8%FY2025 · SEC4th of 655th56th | +18.3%FY2025 · SEC3rd of 661st61st | ———— | ———— | +22.6%FY2025 · SEC2nd of 665th65th | +0.5%FY2025 · SEC6th of 638th38th | +16.1%6 ranked |
| Margins and returns | |||||||||
| Gross margin (Higher is better) | 60.1%FY2025 · SEC4th of 853rd74th | 59.4%FY2025 · SEC5th of 852nd73rd | 33.2%FY2025 · SEC7th of 819th40th | 28.8%FY2025 · SEC8th of 815th33rd | 64.5%FY2025 · SEC2nd of 859th78th | 66.1%FY2025 · SEC1st of 862nd79th | 61.8%FY2025 · SEC3rd of 855th76th | 59.3%FY2025 · SEC6th of 852nd73rd | 59.7%8 ranked |
| Operating margin (Higher is better) | 19.6%FY2025 · SEC3rd of 788th85th | ———— | 14.1%FY2025 · SEC5th of 781st77th | 9.9%FY2025 · SEC6th of 773rd68th | -44.5%FY2025 · SEC7th of 733rd16th | 18.6%FY2025 · SEC4th of 787th84th | 31.6%FY2025 · SEC1st of 795th94th | 25.4%FY2025 · SEC2nd of 793rd91st | 18.6%7 ranked |
| Net margin (Higher is better) | 17.9%FY2025 · SEC5th of 889th87th | 21.6%FY2025 · SEC2nd of 891st91st | 9.0%FY2025 · SEC6th of 878th73rd | 6.3%FY2025 · SEC7th of 872nd65th | -42.4%FY2025 · SEC8th of 832nd16th | 19.6%FY2025 · SEC4th of 889th89th | 24.6%FY2025 · SEC1st of 892nd92nd | 20.3%FY2025 · SEC3rd of 890th89th | 18.8%8 ranked |
| Free cash flow margin (Higher is better) | 23.1%FY2025 · SEC2nd of 892nd91st | 21.1%FY2025 · SEC4th of 889th89th | 12.3%FY2025 · SEC6th of 875th75th | 8.6%FY2025 · SEC7th of 869th66th | -23.7%FY2025 · SEC8th of 836th16th | 21.4%FY2025 · SEC3rd of 890th89th | 24.6%FY2025 · SEC1st of 893rd93rd | 17.1%FY2025 · SEC5th of 884th84th | 19.1%8 ranked |
| Return on equity (Higher is better) | 34.5%FY2025 · SEC2nd of 695th93rd | ———— | 14.2%FY2025 · SEC5th of 686th76th | 10.5%FY2025 · SEC6th of 681st66th | ———— | 33.4%FY2025 · SEC3rd of 695th93rd | 66.2%FY2025 · SEC1st of 698th97th | 29.3%FY2025 · SEC4th of 694th91st | 31.3%6 ranked |
| Return on invested capital (Higher is better) | ———— | ———— | 9.5%FY2025 · SEC3rd of 341st44th | ———— | ———— | ———— | 57.3%FY2025 · SEC1st of 398th97th | 21.0%FY2025 · SEC2nd of 383rd80th | 21.0%3 ranked |
| Valuation | |||||||||
| P/E ratio (Better neither way: ranked highest first) | 30.2×price Oct 22, 2026 · Market data5th of 751st72nd | 34.8×price Oct 21, 2026 · Market data4th of 754th77th | 24.6×price Oct 30, 2026 · Market data7th of 744th63rd | 26.2×price Oct 22, 2026 · Market data6th of 745th66th | ———— | 45.5×price Oct 26, 2026 · Market data2nd of 769th85th | 35.1×price Oct 6, 2026 · Market data3rd of 756th78th | 454.4×price Oct 27, 2026 · Market data1st of 799th99th | 34.8×7 ranked |
| Price to sales (Better neither way: ranked highest first) | 5.9×price Oct 22, 2026 · Market data6th of 861st80th | 7.7×price Oct 21, 2026 · Market data5th of 867th86th | 2.4×price Oct 30, 2026 · Market data7th of 837th52nd | 1.8×price Oct 22, 2026 · Market data8th of 830th45th | 18.8×price Oct 28, 2026 · Market data1st of 882nd94th | 9.0×price Oct 26, 2026 · Market data2nd of 872nd88th | 8.9×price Oct 6, 2026 · Market data3rd of 871st88th | 8.0×price Oct 27, 2026 · Market data4th of 869th86th | 7.9×8 ranked |
| Price to book (Better neither way: ranked highest first) | 10.9×price Oct 22, 2026 · Market data4th of 685th90th | ———— | 3.9×price Oct 30, 2026 · Market data5th of 659th70th | 3.0×price Oct 22, 2026 · Market data6th of 649th62nd | ———— | 15.0×price Oct 26, 2026 · Market data3rd of 690th94th | 25.9×price Oct 6, 2026 · Market data1st of 694th97th | 17.5×price Oct 27, 2026 · Market data2nd of 691st95th | 12.9×6 ranked |
| Free cash flow yield (Higher is better) | 3.6%price Oct 22, 2026 · Market data3rd of 881st57th | 2.6%price Oct 21, 2026 · Market data4th of 878th50th | 4.9%price Oct 30, 2026 · Market data1st of 887th66th | 4.6%price Oct 22, 2026 · Market data2nd of 885th64th | -1.0%price Oct 28, 2026 · Market data8th of 865th34th | 2.3%price Oct 26, 2026 · Market data6th of 876th48th | 2.5%price Oct 6, 2026 · Market data5th of 878th50th | 1.2%price Oct 27, 2026 · Market data7th of 873rd42nd | 2.6%8 ranked |
| Financial strength | |||||||||
| Debt to equity (Lower is better) | ———— | ———— | 0.8×FY2025 · SEC4th of 469th60th | 0.6×FY2025 · SEC3rd of 459th49th | ———— | ———— | 0.3×FY2025 · SEC1st of 438th29th | 0.6×FY2025 · SEC2nd of 456th47th | 0.6×4 ranked |
| Net debt to EBITDA (Lower is better) | ———— | ———— | 2.5×FY2025 · SEC3rd of 361st56th | 2.2×FY2025 · SEC2nd of 354th52nd | ———— | ———— | 0.2×FY2025 · SEC1st of 330th21st | ———— | 2.2×3 ranked |
| Interest cover (Higher is better) | 63.8×FY2025 · SEC1st of 499th97th | ———— | ———— | 6.2×FY2025 · SEC3rd of 487th77th | -112.1×FY2025 · SEC4th of 413th6th | ———— | ———— | 11.5×FY2025 · SEC2nd of 493rd85th | 8.9×4 ranked |
| Piotroski F-score (Higher is better) | —— | 5 of 9FY2025 · SEC4th of 6 | 8 of 9FY2025 · SEC1st of 6 | 8 of 9FY2025 · SEC1st of 6 | 5 of 9FY2025 · SEC4th of 6 | —— | 8 of 9FY2025 · SEC1st of 6 | 4 of 9FY2025 · SEC6th of 6 | 6.5 of 96 ranked |
| Scorecard | |||||||||
| Scorecard (Higher is better) | 18 of 24FY2025 · Scorecard1st of 8 | 11 of 19FY2025 · Scorecard6th of 8 | 18 of 29FY2025 · Scorecard4th of 8 | 20 of 28FY2025 · Scorecard3rd of 8 | 7 of 22FY2025 · Scorecard8th of 8 | 11 of 23FY2025 · Scorecard7th of 8 | 19 of 26FY2025 · Scorecard2nd of 8 | 16 of 26FY2025 · Scorecard5th of 8 | 62% passed8 ranked |
| Valuation checks (Higher is better) | 1 of 6FY2025 · Scorecard3rd of 8 | 1 of 6FY2025 · Scorecard3rd of 8 | 2 of 6FY2025 · Scorecard2nd of 8 | 3 of 6FY2025 · Scorecard1st of 8 | 0 of 5FY2025 · Scorecard6th of 8 | 0 of 6FY2025 · Scorecard6th of 8 | 1 of 6FY2025 · Scorecard3rd of 8 | 0 of 6FY2025 · Scorecard6th of 8 | 17% passed8 ranked |
| Growth checks (Higher is better) | 6 of 6FY2025 · Scorecard1st of 8 | 4 of 6FY2025 · Scorecard3rd of 8 | 3 of 6FY2025 · Scorecard7th of 8 | 4 of 6FY2025 · Scorecard3rd of 8 | 4 of 6FY2025 · Scorecard3rd of 8 | 2 of 6FY2025 · Scorecard8th of 8 | 6 of 6FY2025 · Scorecard1st of 8 | 4 of 6FY2025 · Scorecard3rd of 8 | 67% passed8 ranked |
| Profitability checks (Higher is better) | 5 of 5FY2025 · Scorecard1st of 8 | 2 of 2FY2025 · Scorecard1st of 8 | 3 of 6FY2025 · Scorecard7th of 8 | 3 of 5FY2025 · Scorecard6th of 8 | 1 of 4FY2025 · Scorecard8th of 8 | 4 of 5FY2025 · Scorecard5th of 8 | 6 of 6FY2025 · Scorecard1st of 8 | 5 of 6FY2025 · Scorecard4th of 8 | 82% passed8 ranked |
| Financial health checks (Higher is better) | 4 of 4FY2025 · Scorecard1st of 8 | 2 of 2FY2025 · Scorecard1st of 8 | 5 of 5FY2025 · Scorecard1st of 8 | 6 of 6FY2025 · Scorecard1st of 8 | 2 of 4FY2025 · Scorecard8th of 8 | 3 of 3FY2025 · Scorecard1st of 8 | 5 of 5FY2025 · Scorecard1st of 8 | 5 of 5FY2025 · Scorecard1st of 8 | 100% passed8 ranked |
| Shareholder returns checks (Higher is better) | 2 of 3FY2025 · Scorecard3rd of 8 | 2 of 3FY2025 · Scorecard3rd of 8 | 5 of 6FY2025 · Scorecard1st of 8 | 4 of 5FY2025 · Scorecard2nd of 8 | 0 of 3FY2025 · Scorecard8th of 8 | 2 of 3FY2025 · Scorecard3rd of 8 | 1 of 3FY2025 · Scorecard7th of 8 | 2 of 3FY2025 · Scorecard3rd of 8 | 67% passed8 ranked |
| Ownership | |||||||||
| Held by institutions (Better neither way: ranked highest first) | 98.2%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in5th of 8 | 100.2%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in2nd of 8 | 93.3%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in7th of 8 | 95.0%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in6th of 8 | 98.2%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in4th of 8 | 106.3%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in1st of 8 | 93.1%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in8th of 8 | 98.6%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in3rd of 8 | 98.2%8 ranked |
| Institutions holding (Better neither way: ranked highest first) | 1,0542026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in6th of 8 | 8432026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in7th of 8 | 1,1392026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in3rd of 8 | 1,0802026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in5th of 8 | 6732026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in8th of 8 | 1,1112026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in4th of 8 | 1,2782026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in1st of 8 | 1,2182026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in2nd of 8 | 1,0968 ranked |
| Institutional holding, change over the quarter (Better neither way: ranked highest first) | +8.2 pp2026-Q2 against 2026-Q1 · 13F1st of 8 | +4.2 pp2026-Q2 against 2026-Q1 · 13F3rd of 8 | +2.9 pp2026-Q2 against 2026-Q1 · 13F6th of 8 | +3.0 pp2026-Q2 against 2026-Q1 · 13F5th of 8 | -3.8 pp2026-Q2 against 2026-Q1 · 13F8th of 8 | +0.5 pp2026-Q2 against 2026-Q1 · 13F7th of 8 | +3.9 pp2026-Q2 against 2026-Q1 · 13F4th of 8 | +4.5 pp2026-Q2 against 2026-Q1 · 13F2nd of 8 | +3.4 pp8 ranked |
| Dividends | |||||||||
| Dividend yield (Higher is better) | ———— | ———— | 1.3%FY2025 · SEC1st of 261st33rd | 0.9%FY2025 · SEC2nd of 249th24th | ———— | ———— | ———— | ———— | 1.1%2 ranked |
| Shareholder yield (Higher is better) | 1.7%FY2025 · SEC6th of 843rd30th | 2.5%FY2025 · SEC4th of 853rd41st | 2.9%FY2025 · SEC2nd of 859th47th | 2.6%FY2025 · SEC3rd of 856th43rd | 0.2%FY2025 · SEC7th of 818th10th | 1.8%FY2025 · SEC5th of 845th32nd | 2.9%FY2025 · SEC1st of 860th48th | 0.0%FY2025 · SEC8th of 814th7th | 2.1%8 ranked |
| Dividend payout (Better neither way: ranked highest first) | ———— | ———— | 35.6%FY2025 · SEC1st of 265th48th | 27.5%FY2025 · SEC2nd of 251st35th | ———— | ———— | ———— | ———— | 31.5%2 ranked |
| Dividend per share (Better neither way: ranked highest first) | —— | —— | —— | $2.88FY2025 · SEConly one with it | —— | —— | —— | —— | $2.88— |
| Years of dividend raises (Higher is better) | —— | —— | 15to 2025 · SEConly one with it | —— | —— | —— | —— | —— | 15— |
Under each figure: its fiscal year, quarter or date, and its source. ↑ higher is better, ↓ lower is better, · better neither way (ranked highest first). Ranks count only the companies with the figure; percentiles place each company among all the companies of its own sector and country with the figure (ten or more needed).
Sources: SEC = SEC annual reports (10-K, 20-F, 40-F); ESEF = ESEF annual reports (European and UK listed companies); Editors = The company's annual report, entered by value.today editors; Wikidata = Wikidata, citing the annual report; Scorecard = value.today scorecard: thirty checks on the company's statements, worked out daily; 13F = SEC Form 13F holdings reports; SEC = Dividends declared per share in SEC 10-Q and 10-K filings; Profile = The company's latest reported headcount; Market data = DexCom, Inc.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; Mettler-Toledo International Inc.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; Quest Diagnostics Incorporated: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; Labcorp Holdings Inc.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; Guardant Health, Inc.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; Illumina, Inc.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; IDEXX Laboratories, Inc.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; Waters Corporation: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover.
Where each stands in its sector and country: Operating margin#
The dot is the company; the line runs from the 10th to the 90th percentile of all the companies of its sector (or country) with the figure, the box holds the middle half and the tick is the median. Each company's newest fiscal year; figures that divide by the market value only with a market cap at most 60 days old. How percentiles are worked out.
| Company | Operating margin | In its sector | In its country |
|---|---|---|---|
| DexCom, Inc. | 19.6%FY2025 | 88th percentile in Healthcaremedian -7.7%, 674 companies | 85th percentile in USAmedian 3.5%, 2,594 companies |
| Mettler-Toledo International Inc. | — | — | — |
| Quest Diagnostics Incorporated | 14.1%FY2025 | 81st percentile in Healthcaremedian -7.7%, 674 companies | 77th percentile in USAmedian 3.5%, 2,594 companies |
| Labcorp Holdings Inc. | 9.9%FY2025 | 73rd percentile in Healthcaremedian -7.7%, 674 companies | 68th percentile in USAmedian 3.5%, 2,594 companies |
| Guardant Health, Inc. | -44.5%FY2025 | 33rd percentile in Healthcaremedian -7.7%, 674 companies | 16th percentile in USAmedian 3.5%, 2,594 companies |
| Illumina, Inc. | 18.6%FY2025 | 87th percentile in Healthcaremedian -7.7%, 674 companies | 84th percentile in USAmedian 3.5%, 2,594 companies |
| IDEXX Laboratories, Inc. | 31.6%FY2025 | 95th percentile in Healthcaremedian -7.7%, 674 companies | 94th percentile in USAmedian 3.5%, 2,594 companies |
| Waters Corporation | 25.4%FY2025 | 93rd percentile in Healthcaremedian -7.7%, 674 companies | 91st percentile in USAmedian 3.5%, 2,594 companies |
Revenue by fiscal year, and the rank in the group#
Revenue of the fiscal year. US dollars at each year's exchange rate; fiscal years as each company names them. Ranks: 1st is the highest (better neither way).
Revenue
Rank in the group
| Fiscal year | DexCom, Inc. | Mettler-Toledo International Inc. | Quest Diagnostics Incorporated | Labcorp Holdings Inc. | Guardant Health, Inc. | Illumina, Inc. | IDEXX Laboratories, Inc. | Waters Corporation |
|---|---|---|---|---|---|---|---|---|
| 2025 | $4.7 BSEC3rd | $4.0 BSEC6th | $11.0 BSEC2nd | $14.0 BSEC1st | $982 MSEC8th | $4.3 BSEC4th | $4.3 BSEC5th | $3.2 BSEC7th |
| 2024 | $4.0 BSEC4th | $3.9 BSEC6th | $9.9 BSEC2nd | $13.0 BSEC1st | $739 MSEC8th | $4.4 BSEC3rd | $3.9 BSEC5th | $3.0 BSEC7th |
| 2023 | $3.6 BSEC6th | $3.8 BSEC4th | $9.3 BSEC2nd | $12.2 BSEC1st | $564 MSEC8th | $4.5 BSEC3rd | $3.7 BSEC5th | $3.0 BSEC7th |
| 2022 | $2.9 BSEC7th | $3.9 BSEC4th | $9.9 BSEC2nd | $11.9 BSEC1st | $450 MSEC8th | $4.6 BSEC3rd | $3.4 BSEC5th | $3.0 BSEC6th |
| 2021 | $2.4 BSEC7th | $3.7 BSEC4th | $10.8 BSEC2nd | $13.1 BSEC1st | $374 MSEC8th | $4.5 BSEC3rd | $3.2 BSEC5th | $2.8 BSEC6th |
| 2020 | $1.9 BSEC7th | $3.1 BSEC4th | $9.4 BSEC2nd | $14.0 BSEC1st | $287 MSEC8th | $3.2 BSEC3rd | $2.7 BSEC5th | $2.4 BSEC6th |
| 2019 | $1.5 BSEC7th | $3.0 BSEC4th | $7.7 BSEC2nd | $11.6 BSEC1st | $214 MSEC8th | $3.5 BSEC3rd | $2.4 BSEC5th | $2.4 BSEC6th |
| 2018 | $1.0 BSEC7th | $2.9 BSEC4th | $7.5 BSEC2nd | $11.3 BSEC1st | $91 MSEC8th | $3.3 BSEC3rd | $2.2 BSEC6th | $2.4 BSEC5th |
| 2017 | $719 MSEC7th | $2.7 BSEC4th | $7.4 BSEC2nd | $10.3 BSEC1st | $50 MSEC8th | $2.8 BSEC3rd | $2.0 BSEC6th | $2.3 BSEC5th |
| 2016 | $573 MSEC7th | $2.5 BSEC3rd | $7.2 BSEC2nd | $9.6 BSEC1st | $25 MSEC8th | $2.4 BSEC4th | $1.8 BSEC6th | $2.2 BSEC5th |
| 2015 | $402 MSEC7th | $2.4 BSEC3rd | $7.5 BSEC2nd | $8.7 BSEC1st | — | $2.2 BSEC4th | $1.6 BSEC6th | $2.0 BSEC5th |
| 2014 | $259 MSEC7th | $2.5 BSEC3rd | $7.4 BSEC1st | $6.0 BSEC2nd | — | $1.9 BSEC5th | $1.5 BSEC6th | $2.0 BSEC4th |
Sources: SEC = SEC annual reports (10-K, 20-F, 40-F); ESEF = ESEF annual reports (European and UK listed companies); Ed. = The company's annual report, entered by value.today editors; WD = Wikidata, citing the annual report; Cap = value.today market caps (the last of each calendar year). The small ordinal is the rank in the group that year. Hover a figure for its fiscal year end.
Suggested peers of DexCom, Inc.#
Companies of the same industry, within a hundred times its size (market cap), scored out of 100 for industry, size, country and figures on file. How peers are suggested.
- Mettler-Toledo International Inc.MTD · 🇺🇸 USASame industry: Diagnostics and Research · Similar size: $32.5 B market cap against $29.9 B · Same country: USA · Ratios of the last two fiscal years on fileMarket cap $32.5 B (Oct 21, 2026) · revenue $4.0 B (year to December 2025)100 of 100 (industry or sector 50 + size 30 + country 15 + figures on file 5)In the group
- Quest Diagnostics IncorporatedDGX · 🇺🇸 USASame industry: Diagnostics and Research · Similar size: $27.8 B market cap against $29.9 B · Same country: USA · Ratios of the last two fiscal years on fileMarket cap $27.8 B (Oct 30, 2026) · revenue $11.0 B (year to December 2025)100 of 100 (industry or sector 50 + size 30 + country 15 + figures on file 5)In the group
- Labcorp Holdings Inc.LH · 🇺🇸 USASame industry: Diagnostics and Research · Similar size: $26.3 B market cap against $29.9 B · Same country: USA · Ratios of the last two fiscal years on fileMarket cap $26.3 B (Oct 22, 2026) · revenue $14.0 B (year to December 2025)99 of 100 (industry or sector 50 + size 29 + country 15 + figures on file 5)In the group
- Guardant Health, Inc.GH · 🇺🇸 USASame industry: Diagnostics and Research · Similar size: $24.1 B market cap against $29.9 B · Same country: USA · Ratios of the last two fiscal years on fileMarket cap $24.1 B (Oct 28, 2026) · revenue $982 M (year to December 2025)99 of 100 (industry or sector 50 + size 29 + country 15 + figures on file 5)In the group
- Illumina, Inc.ILMN · 🇺🇸 USASame industry: Diagnostics and Research · Similar size: $40.7 B market cap against $29.9 B · Same country: USA · Ratios of the last two fiscal years on fileMarket cap $40.7 B (Oct 26, 2026) · revenue $4.3 B (year to December 2025)98 of 100 (industry or sector 50 + size 28 + country 15 + figures on file 5)In the group
- IDEXX Laboratories, Inc.IDXX · 🇺🇸 USASame industry: Diagnostics and Research · Similar size: $41.5 B market cap against $29.9 B · Same country: USA · Ratios of the last two fiscal years on fileMarket cap $41.5 B (Oct 6, 2026) · revenue $4.3 B (year to December 2025)98 of 100 (industry or sector 50 + size 28 + country 15 + figures on file 5)In the group
- Waters CorporationWAT · 🇺🇸 USASame industry: Diagnostics and Research · Similar size: $44.8 B market cap against $29.9 B · Same country: USA · Ratios of the last two fiscal years on fileMarket cap $44.8 B (Oct 27, 2026) · revenue $3.2 B (year to December 2025)97 of 100 (industry or sector 50 + size 27 + country 15 + figures on file 5)In the group
- IQVIA Holdings Inc.IQV · 🇺🇸 USASame industry: Diagnostics and Research · Similar size: $45.1 B market cap against $29.9 B · Same country: USA · Ratios of the last two fiscal years on fileMarket cap $45.1 B (Oct 27, 2026) · revenue $16.3 B (year to December 2025)97 of 100 (industry or sector 50 + size 27 + country 15 + figures on file 5)+ Add
- Medpace Holdings, Inc.MEDP · 🇺🇸 USASame industry: Diagnostics and Research · Similar size: $19.0 B market cap against $29.9 B · Same country: USA · Ratios of the last two fiscal years on fileMarket cap $19.0 B (Oct 30, 2026) · revenue $2.5 B (year to December 2025)97 of 100 (industry or sector 50 + size 27 + country 15 + figures on file 5)+ Add
- Agilent Technologies, Inc.A · 🇺🇸 USASame industry: Diagnostics and Research · Similar size: $48.8 B market cap against $29.9 B · Same country: USA · Ratios of the last two fiscal years on fileMarket cap $48.8 B (Oct 19, 2026) · revenue $6.9 B (year to October 2025)97 of 100 (industry or sector 50 + size 27 + country 15 + figures on file 5)+ Add
- Revvity, Inc.RVTY · 🇺🇸 USASame industry: Diagnostics and Research · Similar size: $17.6 B market cap against $29.9 B · Same country: USA · Ratios of the last two fiscal years on fileMarket cap $17.6 B (Oct 23, 2026) · revenue $2.9 B (year to December 2025)96 of 100 (industry or sector 50 + size 27 + country 15 + figures on file 5)+ Add
- Charles River Laboratories International, Inc.CRL · 🇺🇸 USASame industry: Diagnostics and Research · Similar size: $17.2 B market cap against $29.9 B · Same country: USA · Ratios of the last two fiscal years on fileMarket cap $17.2 B (Oct 28, 2026) · revenue $4.0 B (year to December 2025)96 of 100 (industry or sector 50 + size 26 + country 15 + figures on file 5)+ Add
Any figure over the years, other peers or a saved group: open this group in the peer workspace.